STRONTIUM RANELATE IS THE DRUG OF CHOICE IN THE TREATMENT OF OSTEOPOROSIS

Abstract

The paper gives the data of current studies, which suggest the dual mechanism of action of strontium ranelate on bone remodeling in postmenopausal osteoporosis (OP): the drug made bone rearrangement balance shift toward a predominance of the processes of new bone formation. Long-term studies dealing with the use of strontium ranelate to treat postmenopausal OP have supported its safety and efficacy. Strontium ranelate is stated to be the drug of choice in treating his pathology, the duration of the therapy may be as long as 8 years. Indications for its use may be further extended after clinical trials.